Tci Wealth Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History

Tci Wealth Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$32.86 - $55.7 $1,182 - $2,005	36 Added 8.16%	477 $18,000
Q4 2022 Feb 06, 2023	BUY	$40.06 - $59.44 $40 - $59	1 Added 0.23%	441 $25,000
Q3 2022 Nov 08, 2022	BUY	$38.53 - $51.78 $231 - $310	6 Added 1.38%	440 $17,000
Q4 2021 Jan 24, 2022	BUY	$31.82 - $40.75 $6,268 - $8,027	197 Added 83.12%	434 $17,000
Q3 2021 Oct 29, 2021	BUY	$38.47 - $46.42 $5,962 - $7,195	155 Added 189.02%	237 $10,000
Q2 2021 Aug 02, 2021	SELL	$38.84 - $51.31 $2,563 - $3,386	-66 Reduced 44.59%	82 $4,000
Q1 2021 Apr 29, 2021	BUY	$39.51 - $51.45 $5,768 - $7,511	146 Added 7300.0%	148 $6,000
Q4 2020 Jan 21, 2021	BUY	$25.81 - $43.62 $51 - $87	2 New	2 $0

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.